{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:00:19Z","timestamp":1793638819197,"version":"4.5.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T00:00:00Z","timestamp":1633305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T00:00:00Z","timestamp":1633305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Resectable pancreatic ductal adenocarcinoma (R-PDAC) often recurs early after radical resection, which is associated with poor prognosis. Predicting early recurrence preoperatively is useful for determining the optimal treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and methods<\/jats:title>\n                <jats:p>One hundred and seventy-eight patients diagnosed with R-PDAC on computed tomography (CT) imaging and undergoing radical resection at Hirosaki University Hospital from 2005 to 2019 were retrospectively analyzed. Patients with recurrence within 6\u00a0months after resection formed the early recurrence (ER) group, while other patients constituted the non-early recurrence (non-ER) group. Early recurrence prediction score (ERP score) was developed using preoperative parameters.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>ER was observed in 45 patients (25.3%). The ER group had significantly higher preoperative CA19-9 (<jats:italic>p<\/jats:italic>\u2009=\u20090.03), serum SPan-1 (<jats:italic>p<\/jats:italic>\u2009=\u20090.006), and CT tumor diameter (<jats:italic>p<\/jats:italic>\u2009=\u20090.01) compared with the non-ER group. The receiver operating characteristic (ROC) curve analysis identified cutoff values for CA19-9 (133\u00a0U\/mL), SPan-1 (78.2\u00a0U\/mL), and preoperative tumor diameter (23\u00a0mm). When the parameter exceeded the cutoff level, 1 point was given, and the total score of the three factors was defined as the ERP score. The group with an ERP score of 3 had postoperative recurrence-free survival (RFS) of 5.5\u00a0months (95% CI 3.02\u20137.98). Multivariate analysis for ER-related perioperative and surgical factors identified ERP score of 3 [odds ratio (OR) 4.63 (95% CI 1.82\u201311.78), <jats:italic>p<\/jats:italic>\u2009=\u20090.0013] and R1 resection [OR 3.20 (95% CI 1.01\u201310.17), <jats:italic>p<\/jats:italic>\u2009=\u20090.049] as independent predictors of ER.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>For R-PDAC, ER could be predicted by the scoring system using preoperative serum CA19-9 and SPan-1 levels and CT tumor diameter, which may have great significance in identifying patients with poor prognoses and avoiding unnecessary surgery.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-021-10866-6","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T07:09:36Z","timestamp":1633417776000},"page":"1281-1293","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma"],"prefix":"10.1245","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0342-1199","authenticated-orcid":false,"given":"Keinosuke","family":"Ishido","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihisa","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiichi","family":"Wakiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taishu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Hakamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,4]]},"reference":[{"issue":"1","key":"10866_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10866_CR2","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913\u201321.","journal-title":"Cancer Res"},{"issue":"2","key":"10866_CR3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MPA.0000000000001230","volume":"48","author":"G Luo","year":"2019","unstructured":"Luo G, Zhang Y, Guo P, Ji H, Xiao Y, Li K. Global patterns and trends in pancreatic cancer incidence: age, period, and birth cohort analysis. Pancreas. 2019;48(2):199\u2013208.","journal-title":"Pancreas"},{"issue":"43","key":"10866_CR4","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","volume":"24","author":"A McGuigan","year":"2018","unstructured":"McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24(43):4846\u201361.","journal-title":"World J Gastroenterol"},{"key":"10866_CR5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.canep.2018.12.001","volume":"58","author":"I Aier","year":"2019","unstructured":"Aier I, Semwal R, Sharma A, Varadwaj PK. A systematic assessment of statistics, risk factors, and underlying features involved in pancreatic cancer. Cancer Epidemiol. 2019;58:104\u201310.","journal-title":"Cancer Epidemiol"},{"issue":"10041","key":"10866_CR6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388(10041):248\u201357.","journal-title":"Lancet"},{"issue":"10073","key":"10866_CR7","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011\u201324.","journal-title":"Lancet"},{"issue":"25","key":"10866_CR8","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395\u2013406.","journal-title":"N Engl J Med"},{"issue":"1","key":"10866_CR9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jamcollsurg.2016.02.009","volume":"223","author":"JR Bergquist","year":"2016","unstructured":"Bergquist JR, Puig CA, Shubert CR, et al. Carbohydrate antigen 19\u20139 elevation in anatomically resectable, early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: a National Cancer Database study. J Am Coll Surg. 2016;223(1):52\u201365.","journal-title":"J Am Coll Surg"},{"issue":"7\u20138","key":"10866_CR10","first-page":"e302","volume":"89","author":"WJ Kim","year":"2019","unstructured":"Kim WJ, Lim TW, Park PJ, Choi SB, Kim WB. Prognostic impact of the combination of the neutrophil-to-lymphocyte ratio and serum carbohydrate antigen 19\u20139 in patients with pancreas head cancer. ANZ J Surg. 2019;89(7\u20138):e302\u20137.","journal-title":"ANZ J Surg"},{"issue":"1","key":"10866_CR11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ags3.12379","volume":"5","author":"K Ishido","year":"2021","unstructured":"Ishido K, Hakamada K, Kimura N, Miura T, Wakiya T. Essential updates 2018\/2019: current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg. 2021;5(1):7\u201323.","journal-title":"Ann Gastroenterol Surg"},{"issue":"5","key":"10866_CR12","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.1016\/j.ijrobp.2010.10.011","volume":"81","author":"TH Kim","year":"2011","unstructured":"Kim TH, Han SS, Park SJ, et al. CA 19\u20139 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011;81(5):e743\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10866_CR13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","volume":"18","author":"S Isaji","year":"2018","unstructured":"Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18(1):2\u201311.","journal-title":"Pancreatology"},{"issue":"12","key":"10866_CR14","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/ans.14131","volume":"87","author":"SK Goh","year":"2017","unstructured":"Goh SK, Gold G, Christophi C, Muralidharan V. Serum carbohydrate antigen 19\u20139 in pancreatic adenocarcinoma: a mini review for surgeons. ANZ J Surg. 2017;87(12):987\u201392.","journal-title":"ANZ J Surg"},{"issue":"3","key":"10866_CR15","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.surg.2018.04.017","volume":"164","author":"SH Shin","year":"2018","unstructured":"Shin SH, Kim SC, Song KB, et al. Chronologic changes in clinical and survival features of pancreatic ductal adenocarcinoma since 2000: a single-center experience with 2,029 patients. Surgery. 2018;164(3):432\u201342.","journal-title":"Surgery"},{"issue":"9","key":"10866_CR16","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/MPA.0000000000001146","volume":"47","author":"S Nakagawa","year":"2018","unstructured":"Nakagawa S, Yamashita YI, Umezaki N, et al. Serum marker score based on prognostic nutrition index, carcinoembryonic antigen, and carbohydrate antigen 19\u20139 is associated with recurrence for patients undergoing surgery for pancreatic ductal adenocarcinoma. Pancreas. 2018;47(9):1130\u20134.","journal-title":"Pancreas"},{"issue":"13","key":"10866_CR17","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1245\/s10434-018-6763-4","volume":"25","author":"CY Lowder","year":"2018","unstructured":"Lowder CY, Metkus J, Epstein J, et al. Clinical implications of extensive lymph node metastases for resected pancreatic cancer. Ann Surg Oncol. 2018;25(13):4004\u201311.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10866_CR18","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1097\/SLA.0000000000002734","volume":"269","author":"VP Groot","year":"2019","unstructured":"Groot VP, Gemenetzis G, Blair AB, et al. Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg. 2019;269(6):1154\u201362.","journal-title":"Ann Surg"},{"issue":"1","key":"10866_CR19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12957-016-1078-z","volume":"15","author":"K Nishio","year":"2017","unstructured":"Nishio K, Kimura K, Amano R, et al. Preoperative predictors for early recurrence of resectable pancreatic cancer. World J Surg Oncol. 2017;15(1):16.","journal-title":"World J Surg Oncol"},{"issue":"5","key":"10866_CR20","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s11605-018-3972-x","volume":"23","author":"T Nakamura","year":"2019","unstructured":"Nakamura T, Asano T, Okamura K, et al. A preoperative prognosticscoring system to predict prognosis for resectable pancreatic cancer: who will benefit from upfront surgery? J Gastrointest Surg. 2019;23(5):990\u20136.","journal-title":"J Gastrointest Surg"},{"issue":"4","key":"10866_CR21","doi-asserted-by":"crossref","first-page":"e1000267","DOI":"10.1371\/journal.pmed.1000267","volume":"7","author":"S Gillen","year":"2010","unstructured":"Gillen S, Schuster T, Meyer Zum B\u00fcschenfelde C, Friess H, Kleeff J. Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267.","journal-title":"PLoS Med"},{"issue":"8","key":"10866_CR22","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/bjs.10870","volume":"105","author":"E Versteijne","year":"2018","unstructured":"Versteijne E, Vogel JA, Besselink MG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105(8):946\u201358.","journal-title":"Br J Surg"},{"key":"10866_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2020.01.001","author":"M Ye","year":"2020","unstructured":"Ye M, Zhang Q, Chen Y, et al. Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis. HPB. 2020. https:\/\/doi.org\/10.1016\/j.hpb.2020.01.001.","journal-title":"HPB"},{"issue":"3","key":"10866_CR24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/SLA.0000000000004155","volume":"272","author":"SA Ahmad","year":"2020","unstructured":"Ahmad SA, Duong M, Sohal DPS, et al. Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus Gemcitabine\/Nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma. Ann Surg. 2020;272(3):481\u20136.","journal-title":"Ann Surg"},{"issue":"3","key":"10866_CR25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","volume":"7","author":"DPS Sohal","year":"2021","unstructured":"Sohal DPS, Duong M, Ahmad SA, et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2021;7(3):421\u20137.","journal-title":"JAMA Oncol"},{"key":"10866_CR26","unstructured":"National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology (NCCN guidelines) pancreatic adenocarcinoma version 1. 2020;"},{"issue":"2","key":"10866_CR27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","volume":"250","author":"PA Clavien","year":"2009","unstructured":"Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187\u201396.","journal-title":"Ann Surg"},{"issue":"1","key":"10866_CR28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.surg.2005.05.001","volume":"138","author":"C Bassi","year":"2005","unstructured":"Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138(1):8\u201313.","journal-title":"Surgery"},{"key":"10866_CR29","unstructured":"Brierley JD GMWC. UICC: TMN classification of malignant tumors. 8th edn. Wiley-Blackwell; 2017."},{"issue":"5","key":"10866_CR30","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s11605-012-1859-9","volume":"16","author":"T Sugiura","year":"2012","unstructured":"Sugiura T, Uesaka K, Kanemoto H, et al. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2012;16(5):977\u201385.","journal-title":"J Gastrointest Surg"},{"issue":"6","key":"10866_CR31","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.pan.2015.09.008","volume":"15","author":"I Matsumoto","year":"2015","unstructured":"Matsumoto I, Murakami Y, Shinzeki M, et al. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: a multi-center retrospective study. Pancreatology. 2015;15(6):674\u201380.","journal-title":"Pancreatology"},{"issue":"2","key":"10866_CR32","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00006676-200208000-00002","volume":"25","author":"M Niedergethmann","year":"2002","unstructured":"Niedergethmann M, Hildenbrand R, Wostbrock B, et al. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas. 2002;25(2):122\u20139.","journal-title":"Pancreas."},{"issue":"11","key":"10866_CR33","first-page":"2412","volume":"7","author":"LL Zhai","year":"2015","unstructured":"Zhai LL, Wu Y, Huang DW, Tang ZG. Increased matrix metalloproteinase-2 expression and reduced tissue factor pathway inhibitor-2 expression correlate with angiogenesis and early postoperative recurrence of pancreatic carcinoma. Am J Transl Res. 2015;7(11):2412\u201322.","journal-title":"Am J Transl Res"},{"issue":"3","key":"10866_CR34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","volume":"297","author":"H Oettle","year":"2007","unstructured":"Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267\u201377.","journal-title":"JAMA"},{"issue":"10073","key":"10866_CR35","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet (London, England). 2017;389(10073):1011\u201324.","journal-title":"Lancet (London, England)."},{"issue":"8","key":"10866_CR36","doi-asserted-by":"crossref","first-page":"e199126","DOI":"10.1001\/jamanetworkopen.2019.9126","volume":"2","author":"SJ Ma","year":"2019","unstructured":"Ma SJ, Oladeru OT, Miccio JA, Iovoli AJ, Hermann GM, Singh AK. Association of timing of adjuvant therapy with survival in patients with resected stage I to II pancreatic cancer. JAMA Netw Open. 2019;2(8):e199126.","journal-title":"JAMA Netw Open."},{"issue":"2","key":"10866_CR37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.hpb.2019.07.008","volume":"22","author":"DK DePeralta","year":"2020","unstructured":"DePeralta DK, Ogami T, Zhou JM, et al. Completion of adjuvant therapy in patients with resected pancreatic cancer. HPB. 2020;22(2):241\u20138.","journal-title":"HPB."},{"issue":"6","key":"10866_CR38","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/BF01542654","volume":"5","author":"H Koprowski","year":"1979","unstructured":"Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet. 1979;5(6):957\u201371.","journal-title":"Somat Cell Genet"},{"issue":"7","key":"10866_CR39","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdr561","volume":"23","author":"JL Humphris","year":"2012","unstructured":"Humphris JL, Chang DK, Johns AL, et al. The prognostic and predictive value of serum CA199 in pancreatic cancer. Ann Oncol. 2012;23(7):1713\u201322.","journal-title":"Ann Oncol"},{"issue":"3","key":"10866_CR40","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/bjs.10415","volume":"104","author":"S Yamashita","year":"2017","unstructured":"Yamashita S, Passot G, Aloia TA, et al. Prognostic value of carbohydrate antigen 19\u20139 in patients undergoing resection of biliary tract cancer. Br J Surg. 2017;104(3):267\u201377.","journal-title":"Br J Surg"},{"issue":"1","key":"10866_CR41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/(SICI)1098-2388(199807\/08)15:1<15::AID-SSU4>3.0.CO;2-Z","volume":"15","author":"A Nakao","year":"1998","unstructured":"Nakao A, Oshima K, Nomoto S, et al. Clinical usefulness of CA-19-9 in pancreatic carcinoma. Sem Surg Oncol. 1998;15(1):15\u201322.","journal-title":"Sem Surg Oncol"},{"key":"10866_CR42","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/1477-7819-12-360","volume":"12","author":"K Kimura","year":"2014","unstructured":"Kimura K, Amano R, Nakata B, et al. Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma. World J Surg Oncol. 2014;12:360.","journal-title":"World J Surg Oncol"},{"issue":"1","key":"10866_CR43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/000313481808400130","volume":"84","author":"T Shimizu","year":"2018","unstructured":"Shimizu T, Asakuma M, Tomioka A, et al. Span-1 and CA19-9 as Predictors of early recurrence and lymph node metastasis for patients with invasive pancreatic cancer after pancreatectomy. Am Surg. 2018;84(1):109\u201313.","journal-title":"Am Surg"},{"issue":"5\u20136","key":"10866_CR44","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1159\/000494382","volume":"59","author":"S Suzuki","year":"2018","unstructured":"Suzuki S, Shimoda M, Shimazaki J, et al. Predictive early recurrence factors of preoperative clinicophysiological findings in pancreatic cancer. Eur Surg Res. 2018;59(5\u20136):329\u201338.","journal-title":"Eur Surg Res"},{"issue":"6","key":"10866_CR45","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/MPA.0000000000001066","volume":"47","author":"H Kurahara","year":"2018","unstructured":"Kurahara H, Maemura K, Mataki Y, et al. A therapeutic strategy for resectable pancreatic cancer based on risk factors of early recurrence. Pancreas. 2018;47(6):753\u20138.","journal-title":"Pancreas"},{"issue":"6","key":"10866_CR46","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.pan.2018.07.001","volume":"18","author":"N Santucci","year":"2018","unstructured":"Santucci N, Facy O, Ortega-Deballon P, Lequeu JB, Rat P, Rat P. CA 19\u20139 predicts resectability of pancreatic cancer even in jaundiced patients. Pancreatology. 2018;18(6):666\u201370.","journal-title":"Pancreatology"},{"issue":"3","key":"10866_CR47","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s11033-020-05245-5","volume":"47","author":"M Herreros-Villanueva","year":"2020","unstructured":"Herreros-Villanueva M, Ruiz-Rebollo L, Montes M, et al. CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort. Mol Biol Rep. 2020;47(3):1583\u20138.","journal-title":"Mol Biol Rep"},{"issue":"14","key":"10866_CR48","first-page":"3924","volume":"48","author":"JJ Ho","year":"1988","unstructured":"Ho JJ, Chung YS, Fujimoto Y, et al. Mucin-like antigens in a human pancreatic cancer cell line identified by murine monoclonal antibodies SPan-1 and YPan-1. Cancer Res. 1988;48(14):3924\u201331.","journal-title":"Cancer Res"},{"issue":"6","key":"10866_CR49","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/00006676-199411000-00003","volume":"9","author":"S Kawa","year":"1994","unstructured":"Kawa S, Tokoo M, Oguchi H, et al. Epitope analysis of SPan-1 and DUPAN-2 using synthesized glycoconjugates sialyllact-N-fucopentaose II and sialyllact-N-tetraose. Pancreas. 1994;9(6):692\u20137.","journal-title":"Pancreas"},{"issue":"7","key":"10866_CR50","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/1097-0142(19900401)65:7<1557::AID-CNCR2820650718>3.0.CO;2-W","volume":"65","author":"S Kiriyama","year":"1990","unstructured":"Kiriyama S, Hayakawa T, Kondo T, et al. Usefulness of a new tumor marker, Span-1, for the diagnosis of pancreatic cancer. Cancer. 1990;65(7):1557\u201361.","journal-title":"Cancer"},{"issue":"2","key":"10866_CR51","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000449041","volume":"34","author":"Y Hosokawa","year":"2017","unstructured":"Hosokawa Y, Nagakawa Y, Sahara Y, Takishita C, Katsumata K, Tsuchida A. Serum SPan-1 is a significant risk factor for early recurrence of pancreatic cancer after curative resection. Dig Surg. 2017;34(2):125\u201332.","journal-title":"Dig Surg"},{"issue":"5","key":"10866_CR52","first-page":"2467","volume":"36","author":"K Numata","year":"2016","unstructured":"Numata K, Morinaga S, Katayama Y, et al. Combining the Glasgow Prognostic Score and serum carbohydrate antigen 19\u20139 level improves the ability to predict early recurrence in resected pancreatic cancer patients receiving adjuvant Gemcitabine. Anticancer Res. 2016;36(5):2467\u201374.","journal-title":"Anticancer Res"},{"issue":"6","key":"10866_CR53","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1080\/00365521.2019.1624816","volume":"54","author":"W Izumo","year":"2019","unstructured":"Izumo W, Higuchi R, Furukawa T, et al. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma. Scand J Gastroenterol. 2019;54(6):780\u20136.","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"10866_CR54","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/bjc.1991.422","volume":"64","author":"S Kawa","year":"1991","unstructured":"Kawa S, Oguchi H, Kobayashi T, et al. Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype. Br J Cancer. 1991;64(5):899\u2013902.","journal-title":"Br J Cancer"},{"key":"10866_CR55","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-4419-7877-6_4","volume":"705","author":"HL Chen","year":"2011","unstructured":"Chen HL. Lewis glyco-epitopes: structure, biosynthesis, and functions. Adv Exp Med Biol. 2011;705:53\u201380.","journal-title":"Adv Exp Med Biol"},{"issue":"20","key":"10866_CR56","first-page":"5501","volume":"47","author":"MA Tempero","year":"1987","unstructured":"Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19\u20139 and Lewis antigens in pancreatic cancer. Cancer Res. 1987;47(20):5501\u20133.","journal-title":"Cancer Res"},{"issue":"5","key":"10866_CR57","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.pan.2012.07.009","volume":"12","author":"K Tsutsumi","year":"2012","unstructured":"Tsutsumi K, Kawamoto H, Hirao K, et al. Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy. Pancreatology. 2012;12(5):409\u201316.","journal-title":"Pancreatology"},{"issue":"6","key":"10866_CR58","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/MPA.0b013e3181a53ee7","volume":"38","author":"K Shibata","year":"2009","unstructured":"Shibata K, Iwaki K, Kai S, Ohta M, Kitano S. Increased levels of both carbohydrate antigen 19\u20139 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma. Pancreas. 2009;38(6):619\u201324.","journal-title":"Pancreas"},{"issue":"3","key":"10866_CR59","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1245\/s10434-020-09022-3","volume":"28","author":"T Miyata","year":"2021","unstructured":"Miyata T, Hayashi H, Yamashita YI, et al. Prognostic value of the preoperative tumor marker index in resected pancreatic ductal adenocarcinoma: a retrospective single-institution study. Ann Surg Oncol. 2021;28(3):1572\u201380.","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 5","key":"10866_CR60","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1245\/s10434-016-5515-6","volume":"23","author":"F Mierke","year":"2016","unstructured":"Mierke F, Hempel S, Distler M, et al. Impact of portal vein involvement from pancreatic cancer on metastatic pattern after surgical resection. Ann Surg Oncol. 2016;23(Suppl 5):730\u20136.","journal-title":"Ann Surg Oncol"},{"issue":"14","key":"10866_CR61","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","volume":"310","author":"H Oettle","year":"2013","unstructured":"Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473\u201381.","journal-title":"JAMA"},{"issue":"8","key":"10866_CR62","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3390\/ijms18081622","volume":"18","author":"S Heinrich","year":"2017","unstructured":"Heinrich S, Lang H. Neoadjuvant therapy of pancreatic cancer: definitions and benefits. Int J Mol Sci. 2017;18(8):1622.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10866_CR63","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1245\/s10434-013-3338-2","volume":"21","author":"RP Merkow","year":"2014","unstructured":"Merkow RP, Bilimoria KY, Bentrem DJ, et al. National assessment of margin status as a quality indicator after pancreatic cancer surgery. Ann Surg Oncol. 2014;21(4):1067\u201374.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10866_CR64","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/SLA.0000000000002557","volume":"269","author":"P Ghaneh","year":"2019","unstructured":"Ghaneh P, Kleeff J, Halloran CM, et al. The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann Surg. 2019;269(3):520\u20139.","journal-title":"Ann Surg"},{"issue":"8","key":"10866_CR65","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/bjs.11115","volume":"106","author":"WS Tummers","year":"2019","unstructured":"Tummers WS, Groen JV, Sibinga Mulder BG, et al. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery. Br J Surg. 2019;106(8):1055\u201365.","journal-title":"Br J Surg"},{"issue":"3","key":"10866_CR66","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s00534-011-0466-6","volume":"19","author":"Y Nimura","year":"2012","unstructured":"Nimura Y, Nagino M, Takao S, et al. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci. 2012;19(3):230\u201341.","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"4","key":"10866_CR67","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/SLA.0000000000000384","volume":"259","author":"JY Jang","year":"2014","unstructured":"Jang JY, Kang MJ, Heo JS, et al. A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg. 2014;259(4):656\u201364.","journal-title":"Ann Surg"},{"issue":"7","key":"10866_CR68","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/jhbp.465","volume":"24","author":"JY Jang","year":"2017","unstructured":"Jang JY, Kang JS, Han Y, et al. Long-term outcomes and recurrence patterns of standard versus extended pancreatectomy for pancreatic head cancer: a multicenter prospective randomized controlled study. J Hepatobiliary Pancreat Sci. 2017;24(7):426\u201333.","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"2","key":"10866_CR69","doi-asserted-by":"crossref","first-page":"e0212805","DOI":"10.1371\/journal.pone.0212805","volume":"14","author":"A Bradley","year":"2019","unstructured":"Bradley A, Van Der Meer R. Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: a Markov decision analysis. PLoS One. 2019;14(2):e0212805.","journal-title":"PLoS One."},{"issue":"2","key":"10866_CR70","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/jjco\/hyy190","volume":"49","author":"F Motoi","year":"2019","unstructured":"Motoi F, Kosuge T, Ueno H, et al. Randomized phase II\/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02\/JSAP05). Jpn J Clin Oncol. 2019;49(2):190\u20134.","journal-title":"Jpn J Clin Oncol."},{"issue":"suppl 4","key":"10866_CR71","doi-asserted-by":"crossref","first-page":"abstr 189","DOI":"10.1200\/JCO.2019.37.4_suppl.189","volume":"37","author":"M Unno","year":"2019","unstructured":"Unno M, Motoi F, Matsuyama Y, et al. Randomized phase II\/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02\/JSAP-05). J Clin Oncol. 2019;37(suppl 4):abstr 189.","journal-title":"J Clin Oncol."},{"issue":"6","key":"10866_CR72","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/cam4.1071","volume":"6","author":"HX Zhan","year":"2017","unstructured":"Zhan HX, Xu JW, Wu D, et al. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. Cancer Med. 2017;6(6):1201\u201319.","journal-title":"Cancer Med"},{"issue":"16","key":"10866_CR73","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","volume":"38","author":"E Versteijne","year":"2020","unstructured":"Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763\u201373.","journal-title":"J Clin Oncol"},{"issue":"1","key":"10866_CR74","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00423-019-01846-2","volume":"405","author":"A Oba","year":"2020","unstructured":"Oba A, Inoue Y, Ono Y, et al. Radiologically occult metastatic pancreatic cancer: how can we avoid unbeneficial resection? Langenbeck\u2019s Arch Surg. 2020;405(1):35\u201341.","journal-title":"Langenbeck's Arch Surg"},{"issue":"5","key":"10866_CR75","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.pan.2020.05.020","volume":"20","author":"H Takahashi","year":"2020","unstructured":"Takahashi H, Yamada D, Asukai K, et al. Clinical implications of the serum CA19-9 level in \u201cbiological borderline resectability\u201d and \u201cbiological downstaging\u201d in the setting of preoperative chemoradiation therapy for pancreatic cancer. Pancreatology. 2020;20(5):919\u201328.","journal-title":"Pancreatology"},{"issue":"6","key":"10866_CR76","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s00534-013-0616-0","volume":"20","author":"S Satoi","year":"2013","unstructured":"Satoi S, Yamaue H, Kato K, et al. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2013;20(6):590\u2013600.","journal-title":"J Hepatobiliary Pancreat Sci."},{"issue":"2","key":"10866_CR77","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/SLA.0000000000003284","volume":"273","author":"MJ Truty","year":"2019","unstructured":"Truty MJ, Kendrick ML, Nagorney DM, et al. Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline\/locally advanced pancreatic cancer. Ann Surg. 2019;273(2):341\u20139.","journal-title":"Ann Surg"},{"issue":"1","key":"10866_CR78","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00066-014-0737-7","volume":"191","author":"H Golcher","year":"2015","unstructured":"Golcher H, Brunner TB, Witzigmann H, et al. Neoadjuvant chemoradiation therapy with gemcitabine\/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol. 2015;191(1):7\u201316.","journal-title":"Strahlenther Onkol"},{"issue":"10","key":"10866_CR79","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s11605-015-2890-4","volume":"19","author":"R Casadei","year":"2015","unstructured":"Casadei R, Di Marco M, Ricci C, et al. Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg. 2015;19(10):1802\u201312.","journal-title":"J Gastrointest Surg"},{"issue":"6","key":"10866_CR80","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S2468-1253(18)30081-5","volume":"3","author":"M Reni","year":"2018","unstructured":"Reni M, Balzano G, Zanon S, et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2\u20133 trial. Lancet Gastroenterol Hepatol. 2018;3(6):413\u201323.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10866_CR81","doi-asserted-by":"crossref","first-page":"e0173960","DOI":"10.1371\/journal.pone.0173960","volume":"12","author":"HW Kim","year":"2017","unstructured":"Kim HW, Lee JC, Lee J, Kim JW, Kim J, Hwang JH. Early versus delayed initiation of adjuvant treatment for pancreatic cancer. PLoS One. 2017;12(3):e0173960.","journal-title":"PLoS One"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-10866-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-021-10866-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-10866-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T15:18:27Z","timestamp":1641223107000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-021-10866-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,4]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10866"],"URL":"https:\/\/doi.org\/10.1245\/s10434-021-10866-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,4]]},"assertion":[{"value":"1 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}